FLT3 exon 14 ins FLT3 C807S
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 C807S in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 Y693C
|
Advanced Solid Tumor
|
resistant
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 Y693C were resistant to treatment with FF-10101 in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 N676K
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 N676K in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 C695S
|
hematologic cancer
|
predicted - resistant
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 C695S were resistant to treatment with FF-10101 in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835A
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835A in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835I
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835I in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835E
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835E in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 F691L FLT3 D835V
|
hematologic cancer
|
predicted - resistant
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD with FLT3 F691L and D835V were moderately resistant to treatment with FF-10101 in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 K429E
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 K429E in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 G697S
|
Advanced Solid Tumor
|
predicted - resistant
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 G697S were moderately resistant to treatment with FF-10101 in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 C694S
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 C694S in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 Y693F
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 Y693F in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835G
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835G in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D698N FLT3 D835V
|
hematologic cancer
|
predicted - resistant
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD with FLT3 D698N and D835V were moderately resistant to treatment with FF-10101 in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D698N
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D698N in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 Y693N
|
Advanced Solid Tumor
|
predicted - resistant
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 Y693N were moderately resistant to treatment with FF-10101 in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 C681S
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 C681S in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835F
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835F in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 C828S
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 C828S in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835N
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835N in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835Y
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 Y693C FLT3 D835V
|
hematologic cancer
|
resistant
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD with FLT3 Y693C and D835V were resistant to treatment with FF-10101 in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835del
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835del in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 C790S
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 C790S in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins
|
Advanced Solid Tumor
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835H
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835H in culture (PMID: 35395091).
|
35395091
|
FLT3 exon 14 ins FLT3 D835V
|
hematologic cancer
|
sensitive
|
FF-10101
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835V in culture (PMID: 35395091).
|
35395091
|